
06/07/2025
🔬 Can AI help decode how antibodies recognize cancer-related proteins like HER2?
This study presents an in silico docking-based strategy to investigate where novel monoclonal antibodies bind to HER2, a key receptor in many aggressive cancers. Using LightDock and AlphaFold, the researchers explored potential binding interfaces—offering crucial insights for diagnostic and therapeutic innovation in oncology.
📝 Emil Stefańczyk, Agata Mitura, Marta Utratna, Magdalena Staniszewska.
🔗 Investigating and evaluating potential antigen binding sites for monoclonal anti-HER2 antibodies: The LightDock approach. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.06.001
📚 CSBJ: https://www.csbj.org/